Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Traditional DMARDs combined with single traditional Chinese medicine agents for refractory rheumatoid arthritis
ChiCTR2100052492Phase 4Not yet recruiting
- Sponsor
- Guangxi Medical University Second Affiliated Hospital
- Start
- Jan 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of salvia miltiorrhiza, matrine, glycyrrhizinate and aconitine in rheumatoid arthritis (RA) (4 arms), sponsored by Guangxi Medical University Second Affiliated Hospital. Primary endpoints: Morning stiffness time, Joint swelling and tenderness and 6 more. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
salvia miltiorrhizamatrineglycyrrhizinateaconitine
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2100052492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052492.